Innovation crisis in drug research is a myth, warn experts

August 7, 2012

They say the real crisis stems from current incentives that reward companies for developing large numbers of new drugs with few clinical advantages over existing ones.

Since the early 2000s, numerous articles and reports have claimed that the pipeline for will soon run dry, write Donald Light from the University of Medicine and Dentistry of New Jersey and Joel Lexchin from York University in Toronto. Yet data indicate that the number of new drugs licensed remains at the long term average range of 15-25 a year.

The authors argue that telling "innovation crisis" stories to politicians and the press "serves as a ploy to attract a range of government protections from free market competition."

Furthermore, independent reviews have concluded that about 85-90% of all new drugs over the past 50 years have provided few benefits and considerable harms.

And, although the industry emphasises how much money it devotes to discovering new drugs, they say most research funds go towards developing scores of minor variations that produce a steady stream of profits. Heavy promotion of these drugs can account for up to 80% of a nation's drug spending, they add.

They also warn that companies exaggerate research and development costs to lobby for more protection from free market competition. Yet, according to an independent analysis, the 1.3% of revenues devoted to discovering new compares with an estimated 25% spent on promotion, giving a ratio of basic research to marketing of 1:19.

So, what can be done to change the business model of the to focus on more cost effective, safer medicines, they ask?

The first step should be to stop approving so many new drugs of little . "EU countries are paying billions more than necessary for drugs that provide little health gain because prices are not being set to reward new drugs in proportion to their clinical value," they say.

They also believe that regulators should be publicly funded "to end industry's capture of its regulator" and that new ways of rewarding innovation should be considered. "This approach would save countries billions in healthcare costs and produce real gains for people's health, they conclude.

A second article argues that manufacturers should have to show how their products compare to existing treatments before approval Jonathan Cylus from the London School of Economics and colleagues say that the benefits of requiring comparative evidence for new drugs outweigh the risks, and would help ensure that the best therapies reach patients.

Raising the evidence standards could also encourage manufacturers to concentrate on the development of new drugs in therapeutic areas with few or no alternatives, they add.

Explore further: New drugs should be compared with existing treatments before approval, say experts

More information:
www.bmj.com/cgi/doi/10.1136/bmj.e4348
www.bmj.com/cgi/doi/10.1136/bmj.e4261

Related Stories

New drugs should be compared with existing treatments before approval, say experts

September 7, 2011
Manufacturers should have to show how their drugs compare to existing treatments before approval to help ensure that the most beneficial and safest therapies reach patients and that limited healthcare resources are invested ...

India probes charges of violations by drugs regulator

May 10, 2012
India's Health Ministry said Thursday it was examining charges that the government's top drug regulatory agency had colluded with pharmaceutical firms to approve drugs without proper clinical trials.

Indian expert panel to probe drugs regulator

May 11, 2012
India's Health Ministry said Friday it had set up an expert panel to review the operations of its drug regulatory agency, accused of colluding with pharmaceutical firms to approve drugs without trials.

Recommended for you

Mind-body therapies immediately reduce unmanageable pain in hospital patients

July 25, 2017
Mindfulness training and hypnotic suggestion significantly reduced acute pain experienced by hospital patients, according to a new study published in the Journal of General Internal Medicine.

Study suggests ending opioid epidemic will take years

July 20, 2017
The question of how to stem the nation's opioid epidemic now has a major detailed response. A new study chaired by University of Virginia School of Law Professor Richard Bonnie provides extensive recommendations for curbing ...

Team-based model reduces prescription opioid use among patients with chronic pain by 40 percent

July 17, 2017
A new, team-based, primary care model is decreasing prescription opioid use among patients with chronic pain by 40 percent, according to a new study out of Boston Medical Center's Grayken Center for Addiction Medicine, which ...

Private clinics' peddling of unproven stem cell treatments is unsafe and unethical

July 7, 2017
Stem cell science is an area of medical research that continues to offer great promise. But as this week's paper in Science Translational Medicine highlights, a growing number of clinics around the globe, including in Australia, ...

Popular heartburn drugs linked to higher death risk

July 4, 2017
Popular heartburn drugs called proton pump inhibitors (PPIs) have been linked to a variety of health problems, including serious kidney damage, bone fractures and dementia. Now, a new study from Washington University School ...

Most reproductive-age women using opioids also use another substance

June 30, 2017
The majority of reproductive-age and pregnant women who use opioids for non-medical purposes also use at least one other substance, ranging from nicotine or alcohol to cocaine, according to a University of Pittsburgh Graduate ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.